EIF4E2: A Potential Drug Target and Biomarker (G9470)

Target Name: EIF4E2

NCBI ID: G9470

EIF4E2

EIF4E2: A Potential Drug Target and Biomarker

EIF4E2 (endoplasmic reticulum-associated protein 4E2) is a protein that is expressed in various tissues and cell types throughout the body. Its primary function is to regulate the transport of proteins from the endoplasmic reticulum (ER) to the cytoplasm. It is a key protein that is involved in the ER-to-cytoplasmic transport of various proteins, including membrane proteins, cytoskeletal proteins, and intracellular signaling proteins.

Recent studies have identified EIF4E2 as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This is due to its involvement in the regulation of protein transport, which is crucial for the proper functioning of various cellular processes.

Drug Target Potential

EIF4E2 has been identified as a potential drug target due to its involvement in the regulation of protein transport. Its function in regulating protein transport from the ER to the cytoplasm makes it an attractive target for small molecules that can inhibit its activity and disrupt its regulation of protein transport. This could lead to the inhibition of protein synthesis and the inhibition of cellular processes that rely on the proper functioning of proteins.

EIF4E2 has been shown to play a role in the regulation of protein transport in various cell types, including cancer cells. For example, studies have shown that inhibitors of EIF4E2 can disrupt the proper functioning of the endoplasmic reticulum and disrupt the transport of proteins to the cytoplasm, leading to the inhibition of protein synthesis and the inhibition of cellular processes.

Biomarker Potential

EIF4E2 has also been identified as a potential biomarker for various diseases. Its involvement in the regulation of protein transport makes it an attractive target for diagnostic tools that can identify changes in protein transport that may indicate the presence of certain diseases.

Studies have shown that EIF4E2 is involved in the regulation of protein transport in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, studies have shown that EIF4E2 is involved in the regulation of protein transport in neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

In addition, EIF4E2 has also been shown to be involved in the regulation of protein transport in cancer, as it has been shown to play a role in the regulation of protein synthesis and the inhibition of cellular processes that rely on the proper functioning of proteins.

Conclusion

In conclusion, EIF4E2 is a protein that has been identified as a potential drug target and biomarker for various diseases due to its involvement in the regulation of protein transport. Its involvement in the regulation of protein transport makes it an attractive target for small molecules that can inhibit its activity and disrupt its regulation of protein transport. Further studies are needed to fully understand the role of EIF4E2 in the regulation of protein transport and its potential as a drug target and biomarker.

Protein Name: Eukaryotic Translation Initiation Factor 4E Family Member 2

Functions: Recognizes and binds the 7-methylguanosine-containing mRNA cap during an early step in the initiation (PubMed:17368478, PubMed:25624349, PubMed:9582349). Acts as a repressor of translation initiation (PubMed:22751931). In contrast to EIF4E, it is unable to bind eIF4G (EIF4G1, EIF4G2 or EIF4G3), suggesting that it acts by competing with EIF4E and block assembly of eIF4F at the cap (By similarity). In P-bodies, component of a complex that promotes miRNA-mediated translational repression (PubMed:28487484)

The "EIF4E2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EIF4E2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets